2026-09-02T21:35:08.000Z · 4 weeks ago BioRestorative Therapies announces 1-for-20 reverse stock split
2026-06-25T12:20:21.000Z · 3 months ago BioRestorative Therapies completes manufacturing for BRTX-100
Jun 25, 2026, 8:15 AM EDT · 3 months ago BioRestorative Therapies Announces Completion of BRTX-100 Phase 2 Manufacturing, Highlighting Integrated Regenerative Biologics Platform
2026-06-18T12:31:51.000Z · 3 months ago BioRestorative Therapies appoints Smith as VP of Biocosmeceuticals Division
Jun 18, 2026, 8:15 AM EDT · 3 months ago BioRestorative Therapies Strengthens Leadership with Appointment of Healthcare Executive Zachary Smith as Vice President of Biocosmeceuticals Division to Accelerate Commercial Expansion and Strategic Growth
2026-05-27T12:10:07.000Z · 4 months ago BioRestorative Therapies shareholder Kaos Capital acquires 4.9% stake
May 27, 2026, 7:45 AM EDT · 4 months ago Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)
2026-05-26T16:05:13.000Z · 4 months ago BioRestorative Therapies completes Phase 2 dosing of BRTX-100
May 26, 2026, 11:00 AM EDT · 4 months ago BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data
2026-05-13T18:18:04.000Z · 4 months ago BioRestorative Therapies presents preclinical data on MSC exosome proteomics
May 13, 2026, 11:00 AM EDT · 4 months ago BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticals
2026-05-07T17:39:05.000Z · 4 months ago BioRestorative Therapies reports expanded Phase 2 blinded dataset for BRTX-100
May 7, 2026, 12:00 PM EDT · 4 months ago BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease
Apr 30, 2026, 10:36 AM EDT · 5 months ago BioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical Platform
2026-04-21T13:19:35.000Z · 5 months ago BioRestorative Therapies announces partnership with David Goldberg, M.D.
Apr 21, 2026, 8:00 AM EDT · 5 months ago BioRestorative Therapies Announces Strategic Partnership with Global Dermatology Leader Dr. David J. Goldberg to Lead Clinical Evaluation and Seek Multi-Channel Adoption of Its Regenerative BioCosmeceutical Platform
2026-04-07T14:23:38.000Z · 5 months ago BioRestorative Therapies announces strategic collaboration with 203 Creates
Apr 7, 2026, 8:15 AM EDT · 5 months ago BioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical Platform
2026-04-02T12:00:42.000Z · 6 months ago BioRestorative Therapies price target lowered to $15 from $18 at Roth Capital
2026-03-30T12:53:07.000Z · 6 months ago BioRestorative Therapies reports blinded data from mesenchymal stem cells trial
Mar 30, 2026, 8:00 AM EDT · 6 months ago BioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease
Mar 19, 2026, 8:00 AM EDT · 6 months ago BioRestorative Therapies to Present Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease
Mar 5, 2026, 8:00 AM EST · 7 months ago BioRestorative Therapies, Inc. to Participate in the Be+Well Beauty and Wellness Show in New York City, March 8-10, 2026
2026-02-24T13:45:03.000Z · 7 months ago BioRestorative Therapies expands global protection for ThermoStem
Feb 24, 2026, 8:30 AM EST · 7 months ago BioRestorative Expands Global Protection for ThermoStem®, a Potentially Longer-Lasting and Safer Cell-Based Alternative to GLP-1 Drugs
Feb 13, 2026, 8:30 PM EST · 7 months ago BioRestorative Announces Closing of $5.0 Million Public Offering
2026-02-12T12:50:13.000Z · 7 months ago BioRestorative Therapies prices $5.0M public offering of common stock at $0.35
Feb 11, 2026, 10:30 PM EST · 7 months ago BioRestorative Announces Pricing of $5.0 Million Public Offering
2026-02-11T12:40:48.000Z · 7 months ago BioRestorative Therapies expects to sumbit Phase 3 trial IND in 2H26
Feb 11, 2026, 7:30 AM EST · 7 months ago BioRestorative Announces Positive Outcome from Type B Meeting with FDA
2026-02-10T13:11:31.000Z · 7 months ago BioRestorative completes patient enrollment in Phase 2 trial of BTRX-100
Nov 5, 2025, 4:30 PM EST · 11 months ago BioRestorative Therapies to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025
Oct 27, 2025, 7:30 AM EDT · 11 months ago BioRestorative Awarded Notice of Allowance for Japanese Patent – Expands Protection for Potential Cell-Based Alternative to Multi-Billion Dollar GLP-1 Drug Market
Oct 22, 2025, 9:35 AM EDT · 11 months ago BioRestorative Strengthens Commercial Leadership with Appointment of Crystal Romano as Head of Global Commercial Operations to Accelerate Growth of Cell-Based Product Portfolio
Oct 15, 2025, 9:35 AM EDT · 11 months ago BioRestorative Therapies to Participate in the 2025 Maxim Growth Summit
Oct 7, 2025, 9:25 AM EDT · 12 months ago BioRestorative CEO Lance Alstodt Interviewed on “The Big Biz Show”
Oct 6, 2025, 2:28 PM EDT · 12 months ago BioRestorative Therapies Announces $1.085 Million Registered Direct Offering Priced Above Market
Aug 5, 2025, 4:30 PM EDT · 1 year ago BioRestorative Therapies to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025
Jun 18, 2025, 9:35 AM EDT · 1 year ago BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Compelling BRTX-100 Clinical Data, Leadership Enhancements and Strategic updates
Jun 13, 2025, 7:45 AM EDT · 1 year ago BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 – an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc Disease
Jun 9, 2025, 7:45 AM EDT · 1 year ago BioRestorative to Present Major Update on Promising Preliminary Phase 2 BRTX-100 Data at ISSCR 2025
May 13, 2025, 9:15 AM EDT · 1 year ago Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data
May 8, 2025, 4:30 PM EDT · 1 year ago BioRestorative Therapies to Report First Quarter 2025 Financial Results and Host Conference Call on May 14, 2025
May 7, 2025, 9:15 AM EDT · 1 year ago BioRestorative to Present a BRTX-100 Clinical Update at ISCT 2025
Apr 15, 2025, 8:30 AM EDT · 1 year ago BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Recent Achievements of Key Clinical & Regulatory Milestones, and Highlight Commercial Opportunities
Apr 10, 2025, 9:15 AM EDT · 1 year ago BioRestorative Confirms No Material Impact from Reciprocal Tariffs; All BRTX-100 Production & Manufacturing Performed in the United States
Feb 27, 2025, 9:45 AM EST · 1 year ago BioRestorative Announces FDA Clearance of IND for Phase 2 Trial of BRTX-100 in Chronic Cervical Discogenic Pain
Feb 26, 2025, 8:15 PM EST · 1 year ago BioRestorative Announces Updated Time for February 27th Webcasted Conference Call to Discuss Clinical Pipeline Update
Feb 20, 2025, 8:30 AM EST · 1 year ago BioRestorative Receives FDA Fast Track Designation for BRTX-100 Chronic Lumbar Disc Disease Program
Dec 5, 2024, 6:45 AM EST · 1 year ago BioRestorative Therapies Announces Notice of Allowance of Key New Patent Protecting ThermoStem® Metabolic Disease Program
Nov 5, 2024, 7:10 AM EST · 1 year ago BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health
Oct 3, 2024, 4:15 PM EDT · 2 years ago BioRestorative Therapies to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
Sep 19, 2024, 6:55 AM EDT · 2 years ago BioRestorative Therapies' IFATS 2024 Presentation to Feature ThermoStem® Platform's Potential to Deliver a Superior Efficacy and Tolerability Profile Over GLP-1 Drugs
Jul 23, 2024, 7:10 AM EDT · 2 years ago BioRestorative Therapies' Chief Scientist Named New Section Editor of the Prestigious Journal of Translational Medicine
Jun 27, 2024, 7:40 AM EDT · 2 years ago BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program
Jun 17, 2024, 7:05 AM EDT · 2 years ago BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results
Jun 13, 2024, 7:00 AM EDT · 2 years ago BioRestorative Therapies in Substantive Discussions for Potential License Agreement for ThermoStem® Metabolic Disease Program
Jun 4, 2024, 8:50 AM EDT · 2 years ago BioRestorative Therapies, Inc. to attend the Jefferies 2024 Healthcare Conference
May 24, 2024, 7:45 PM EDT · 2 years ago BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice
May 15, 2024, 9:00 AM EDT · 2 years ago BioRestorative Therapies (NASDAQ:BRTX) Announces Commercial Agreement With Cartessa, Further Expanding Into $75.46 Billion Aesthetics Market
May 14, 2024, 4:10 PM EDT · 2 years ago BioRestorative Therapies Provides First Quarter 2024 Business Update
May 8, 2024, 7:30 AM EDT · 2 years ago BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting Obesity
Apr 30, 2024, 4:15 PM EDT · 2 years ago BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024